AUG 22, 2013 7:00 AM PDT

Soluble 14-3-3? - A Personalised Rheumatoid Arthritis Patient Management Strategy

Speaker
  • Chief Scientific Officer, AugureX Life Sciences Corp
    Biography
      Anthony serves as the Chief Scientific Officer at Augurex Life Sciences Corp, a company that he co-founded with CEO, Mrs. Norma Biln. Anthony's creativity and business acumen have set him apart from most scientific leaders. Anthony has worked in the life sciences space for 20 years and has consistently created progressive opportunities that have delivered great returns for companies that he has been involved with. He received his PhD from the Faculty of Medicine at the University of British Columbia in Vancouver, Canada.

    Abstract
    Rheumatoid Arthritis (RA) is a heterogenous disease that affects 1.5% of the population. Similar to cancer, early detection coupled with an effective treatment strategy can significantly improve patient outcomes. In the advent of new classes of RA therapies, there is an impetus to identify new serological markers that mark risk of RA development, prognosis and therapy response. 14-3-3 eta (?) is a new RA marker that is available for clinical use in the US through Quest Diagnostics. 14-3-3? is one of 7 members of the 14-3-3 family and is specifically present in the serum of patients with RA and erosive psoriatic arthritis (PsA). In the healthy state, these proteins reside within the intracellular space governing various biological processes including proliferation, differentiation and metabolism. Increased expression of different 14-3-3 isoforms correspond with worse prognosis in certain cancers and neurological disorders. In RA, the 14-3-3? protein is specifically externalized and can be measured in serum, making it a useful clinical serum marker. When 14-3-3? exists in the extracellular environment, it behaves as a soluble ligand inducing factors that drive inflammation and joint damage also making it a novel therapeutic target. This presentation will describe the discovery of 14-3-3? in arthritis, its development pathway and the biomarker's clinical utility. We will discuss how the 14-3-3? biomarker pipeline has evolved from the protein R&D programs into a 14-3-3? biomarker suite that serves as a direct companion to a first-in-class RA personalized medicine drug target.

    Show Resources
    You May Also Like
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    Loading Comments...
    Show Resources